Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ALS therapy: targets for the future

J Hugon1

  • 1Unit of Neurobiology, UCNRS 1485, Faculty of Medicine, Limoges, France.

Neurology
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Amyotrophic lateral sclerosis (ALS) may stem from excitotoxicity, gene mutations, autoantibodies, or neurofilament issues. Combined therapies targeting these mechanisms offer future treatment potential for motoneuron degeneration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration.

The European physical journal. C, Particles and fields·2021
Same author

Is there a link between headache and cognitive disorders? A systematic review.

Revue neurologique·2021
Same author

Chronic traumatic encephalopathy.

Neuro-Chirurgie·2021
Same author

Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC).

NeuroImage. Clinical·2019
Same author

Diagnosis associated with Tau higher than 1200 pg/mL: Insights from the clinical and laboratory practice.

Clinica chimica acta; international journal of clinical chemistry·2019
Same author

Search for direct pair production of supersymmetric top quarks decaying to all-hadronic final states in pp collisions at [Formula: see text].

The European physical journal. C, Particles and fields·2017
Same journal

Teaching Video NeuroImage: Tardive Blepharoclonus.

Neurology·2026
Same journal

Teaching NeuroImage: Latent Axonal Degeneration in Patient With Anterior Circulation Stroke.

Neurology·2026
Same journal

Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

Neurology·2026
Same journal

Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

Neurology·2026
Same journal

Digital Semiology.

Neurology·2026
Same journal

Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

Neurology·2026
See all related articles

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motoneuron degeneration.
  • Several hypotheses exist regarding the underlying causes of ALS, including excitotoxicity, genetic mutations, autoimmune responses, and protein accumulation.

Purpose of the Study:

  • To review the primary hypotheses concerning the etiology of ALS.
  • To explore potential therapeutic strategies based on these etiological mechanisms.

Main Methods:

  • Literature review of current hypotheses on ALS pathogenesis.
  • Analysis of potential therapeutic targets and combination strategies.

Main Results:

  • Four main hypotheses for ALS causation are identified: glutamate receptor overactivation (excitotoxicity), superoxide dismutase gene mutations, autoantibodies against calcium channels, and neurofilament accumulation.

Related Experiment Videos

  • Motoneuron degeneration in ALS may result from one or a combination of these factors.

    • Conclusions:

    • Future ALS therapies should integrate approaches targeting multiple etiological mechanisms simultaneously.
    • Potential treatments include neuroprotective agents (antiglutamates, NMDA/non-NMDA antagonists, free-radical scavengers, calcium-channel blockers, neurotrophic factors) and gene transfer strategies for identified mutations.